Protective effects and mechanism of resveratrol in animal models of pulmonary fibrosis: a preclinical systematic review and meta-analysis
Frontiers in Pharmacology · 29.09.2025 · 16
DOI: 10.3389/fphar.2025.1666698 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.09.2025. Verfasst von Yajie Yin und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Affiliated Hospital of Chengdu University of Traditional Chinese Med…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Pulmonary fibrosis (PF) is a chronic lung disease characterized by ongoing interstitial scarring. Current treatments can only slow the progression of the disease. Resveratrol (RES), a natural polyphenolic compound, has become a potential therapy for PF because of its multiple biological effects, including anti-fibrotic, anti-inflammatory, and antioxidant properties.
Objectives
To clarify RES’s efficacy, safety, and mechanism of action in treating PF through a preclinical systematic review.
Methods
A computerized search of eight databases (up to 6 March 2025) was conducted to identify in vivo animal experiments on RES treatment for PF. The SYRCLE tool was used to assess the risk of bias, and meta-analysis was performed using RevMan 5.4 and Stata 17.0. The outcome measures included two main aspects: core pathological processes and molecular mechanisms. Heterogeneity was assessed with the I 2 test, and publication bias was evaluated using funnel plots and Egger’s test.
Results
A total of 25 studies were included, involving 628 animals in the experimental groups and 357 animals in the control groups. Meta-analysis of selected outcome measures showed: 1. Improved fibrosis: significant reduction in pulmonary fibrosis score (SMD = −2.30, 95% CI [−2.80, −1.79], p < 0.00001, I 2 = 76%) and decreased Hyp content (SMD = −2.16, 95% CI [−2.69, −1.63], p < 0.00001, I 2 = 85%); 2. Inhibited inflammation: reduced TNF-α content (SMD = −1.58, 95% CI [−2.18, −0.99], p < 0.00001, I 2 = 70%) and decreased IL-6 content (SMD = −2.16, 95% CI [−2.74, −1.59], p = 0.007, I 2 = 57%); 3. Restored oxidative balance: decreased MDA content (SMD = −2.22, 95% CI [−3.09, −1.35], p = 0.06, I 2 = 55%) and increased SOD content (SMD = 1.67, 95% CI [1.05, 2.30], p < 0.0001, I 2 = 76%).
Conclusion
RES significantly enhances the pathological process in PF animal models by regulating the TGF-β/Smad and NF-κB pathways. Future efforts should focus on optimizing preclinical study designs to decrease heterogeneity and improve clinical translation. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/ , Identifier CRD420251009847.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
- Chengdu Shuangliu Area Gongxing Community Health Service Centers, Chengdu, Sichuan, China.
- Chengdu Integrated TCM&Western Medicine Hospital, Chengdu, Sichuan, China.
- Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
- Department of Geriatrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yin, Y., Jia, N., Luo, H., Feng, X., He, X., Huang, J., & Wang, F. (2025). Protective effects and mechanism of resveratrol in animal models of pulmonary fibrosis: a preclinical systematic review and meta-analysis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1666698
Vancouver
Yin Y, Jia N, Luo H, Feng X, He X, Huang J, et al. Protective effects and mechanism of resveratrol in animal models of pulmonary fibrosis: a preclinical systematic review and meta-analysis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1666698
BibTeX
@article{Yin2025,
author = {Yin, Yajie and Jia, Nan and Luo, Hui and Feng, Xinglin and He, Xin and Huang, Ju and Wang, Fei},
title = {Protective effects and mechanism of resveratrol in animal models of pulmonary fibrosis: a preclinical systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1666698}
}
EUVIMED